Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756738 | 1.00 | CTSL (0.50) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL1928095 | 0.91 | TSHR (0.58) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL17019782 | 0.91 | TSHR (0.58) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL600663 | 0.86 | TSHR (0.48) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL599909 | 0.86 | TSHR (0.48) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL17043033 | 0.86 | CTSL (0.50) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL17043168 | 0.86 | CTSL (0.50) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL17043034 | 0.86 | CTSL (0.50) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL6748142 | 0.84 | CTSL (0.51) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL4677170 | 0.83 | TSHR (0.54) | CTSLCTSBCTSKTSHRNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3342767-B1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190270731-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-05 | — | — | US | disclosed |
| EP-3342767-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180030039-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-9663500-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150191455-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-9012478-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8759365-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-8193349-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193349-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100311750-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311750-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| EP-0798298-B1 | THIAZOLIDINONE OR OXAZOLIDINONE DERIVATIVES TO TREAT ANGINA PECTORIS OR COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT | SANKYO CO (JP) | 2001-08-08 | — | — | EP | disclosed |
| US-5843973-A | Thiazolidinone compounds and composition for angina pectoris comprising the compounds as an active ingredient | SANKYO COMPANY, LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0798298-A1 | THIAZOLIDINONE COMPOUNDS OR ANGINA PECTORIS REMEDY OR PREVENTIVE CONTAINING THE SAME AS ACTIVE INGREDIENT | SANKYO COMPANY LIMITED (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | CTSL 3961/4885CTSB 3686/4885CTSK 3183/4885 |
| US-20150191455-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | CTSL 3961/4885CTSB 3686/4885CTSK 3183/4885 |
| US-20090118287-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CTSL 1325/4885CTSB 289/4885CTSK 581/4885 |
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | PTGIR, PTGIS, PTGER1 | CTSL 3961/4885CTSB 3686/4885CTSK 3183/4885 |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | CTSL 3961/4885CTSB 3686/4885CTSK 3183/4885 |
| US-20180030039-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | CTSL 3961/4885CTSB 3686/4885CTSK 3183/4885 |
| US-20190270731-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | CTSL 3961/4885CTSB 3686/4885CTSK 3183/4885 |
| US-20100311750-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CTSL 1420/4885CTSB 333/4885CTSK 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.